BillionToOne

BillionToOne's QCT platform chemically tags individual DNA molecules with unique barcodes, then amplifies and counts them on standard qPCR instruments. This pushes single-molecule sensitivity — comparable to digital PCR — onto hardware that every clinical lab already owns. The approach avoids the capital expenditure and workflow complexity of next-generation sequencing, making high-resolution molecular testing accessible outside of reference labs and academic medical centers.

Co-founder and CEO Oguzhan Atay leads strategic capital allocation, supported by a board that includes representatives from Adams Street Partners and Hummingbird Ventures following the 2023 Series D. The company does not operate a family-office structure; it is a venture-backed private corporation with standard fiduciary governance. Atay and co-founder David Tsao hold meaningful voting control through a dual-class share structure.

Revenue comes primarily from third-party payer reimbursement for laboratory-developed tests, including commercial health plans and Medicare. The Unity prenatal screen and Northstar colorectal cancer test are billed as in-network or Medicare-covered services, with specimen collection happening in routine clinical settings. BillionToOne does not sell instruments; its business model is consumable and service-based.

BillionToOne is an operating diagnostics company, not an investment firm. It raises venture capital to fund commercial expansion and R&D, most recently closing a $130 million Series D in June 2023. Institutional investors participate through equity rounds, not through fund commitments or co-investment sidecars. The company has not disclosed plans for a public offering, though its revenue scale and reimbursement milestones are consistent with late-stage private diagnostics firms approaching registration readiness.

No publicly disclosed philanthropic foundation or donor-advised fund is associated with BillionToOne or its founders. The company operates a commercial testing program — the BillionToOne Compassionate Care Program — which provides financial assistance to underinsured patients for out-of-pocket testing costs, but this is a patient-access initiative embedded within the corporate entity, not a separate philanthropic vehicle.

BillionToOne focuses strictly on molecular diagnostics for reproductive health and oncology. It does not develop therapeutics, medical devices, imaging platforms, or consumer wellness products. Its QCT platform is not applied to infectious disease, direct-to-consumer genetic testing, or agricultural biotechnology. The firm has publicly stated its pipeline remains within prenatal and oncology indications.

Unlike Guardant Health or Natera, which depend heavily on next-generation sequencing infrastructure, BillionToOne runs on qPCR — the most ubiquitous molecular biology instrument in clinical labs. This lowers the adoption barrier and concentrates its competitive advantage in assay chemistry and counting algorithms rather than hardware sales. BillionToOne competes directly in the noninvasive prenatal testing and colorectal cancer screening markets but with a fundamentally different instrumentation strategy.